epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-620, Phase III. In planning

Chronic obstructive pulmonary disease with frequent exacerbations

LWR-620 against placebo to reduce exacerbations in COPD. Sponsor: Litware Respiratory (fictional), Respiratory.

Where EPI-620 stands on September 30th 2026

  • Randomised0of 706 needed
  • Sites open0of 0 planned
  • Median forecast finish–Deadline Jul 2029
  • FinishIn planningThe Plan tab sizes the sites needed to meet the deadline.Open the plan
  • EnrolmentNo sites yetNothing to judge until sites open.Open KPIs
  • SitesNo sites yetNothing to judge until sites open.Open Sites
  • KRIsNo sites yetNothing to judge until sites open.Open KRIs
  • QTLsNo sites yetNothing to judge until sites open.Open QTLs

By country

No sites have opened yet.